Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $106.25

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $106.25.

Several brokerages have weighed in on PCVX. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 target price for the company. Cowen reiterated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vaxcyte in a report on Saturday, September 27th.

Institutional Trading of Vaxcyte

A number of hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. lifted its holdings in Vaxcyte by 358.5% during the third quarter. Assenagon Asset Management S.A. now owns 219,950 shares of the company’s stock worth $7,923,000 after buying an additional 171,974 shares during the period. Osaic Holdings Inc. lifted its holdings in Vaxcyte by 110.8% during the second quarter. Osaic Holdings Inc. now owns 3,859 shares of the company’s stock worth $128,000 after buying an additional 2,028 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vaxcyte by 23.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 31,910 shares of the company’s stock valued at $1,037,000 after purchasing an additional 6,083 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at $728,000. Finally, Nomura Holdings Inc. purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at $1,301,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Up 4.1%

Shares of NASDAQ:PCVX opened at $43.70 on Wednesday. The business’s 50 day moving average is $33.48 and its 200 day moving average is $34.15. The stock has a market cap of $5.67 billion, a P/E ratio of -10.63 and a beta of 1.12. Vaxcyte has a 52-week low of $27.66 and a 52-week high of $118.62.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period last year, the firm posted ($1.10) earnings per share. On average, sell-side analysts anticipate that Vaxcyte will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.